May 19, 2020 / 01:45PM GMT
Kennen B. MacKay - RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi, this is Kennen MacKay from RBC, and it's my great pleasure to kick off the first of my fireside chats with Regeneron. And from Regeneron, I'm joined by Bob Landry, the Executive Vice President of Finance and the Chief Financial Officer of Regeneron.
Bob, thank you so much for joining us this morning.
Robert E. Landry - Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Kennen, thanks for the invite. This is kind of inaugural for Regeneron to be with RBC, and we're very, very happy. Again, I wish we could be in person. And I hope everyone out there listening is -- are staying very, very safe in this trying times.
Let me open up with our FLS and then get into some opening comments. So again, I'd like to remind you that remarks made on the webcast, they include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and business, financial
Regeneron Pharmaceuticals Inc at RBC Global Healthcare Conference Transcript
May 19, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers